# Bergacyn (Bergamot and Cynara cardunculus Extracts)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bergacyn
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Bergamot Polyphenolic Fraction + Cynara cardunculus Extract, BPF-Cynara combination, Citrus bergamia-Cynara cardunculus blend, Bergamot-Wild Cardoon Extract, Mediterranean Liver Support Complex

## Overview

Bergacyn is a patented combination of bergamot polyphenol fraction and Cynara cardunculus (artichoke) extract that targets both hepatic lipid [metabolism](/ingredients/condition/weight-management) and systemic cholesterol regulation. Its primary mechanism involves activating AMPK and inhibiting HMG-CoA reductase activity while promoting bile acid synthesis to reduce liver fat accumulation and improve lipid profiles.

## Health Benefits

• Reduces liver fat accumulation in non-alcoholic fatty liver disease (NAFLD) - demonstrated in RCT with diabetic patients (PMID: 32670822)
• Improves cholesterol profile by lowering LDL-C, triglycerides, and total cholesterol - shown in 8-24 week trials with dyslipidemic subjects (PMID: 31225673)
• Enhances vascular function through improved NO-mediated vasodilation - evidence from controlled trial in T2DM patients (PMID: 32670822)
• Reduces [inflammatory](/ingredients/condition/inflammation) markers including TNF-α and hs-CRP - demonstrated in randomized controlled trial over 8-24 weeks (PMID: 31225673)
• Supports weight management and reduces hepatic steatosis - shown in RCT with non-diabetic adults aged 30-75 (PMC9784233)

## Mechanism of Action

Bergamot polyphenols — particularly naringenin, hesperidin, and bruteridin — activate AMP-activated protein kinase (AMPK), suppressing de novo lipogenesis and promoting fatty acid beta-oxidation in hepatocytes, thereby reducing intrahepatic triglyceride accumulation. Cynara cardunculus compounds, including luteolin and cynarin, inhibit HMG-CoA reductase (the same enzymatic target as statins) and upregulate LDL receptor expression in the liver, enhancing circulating LDL clearance. Together, these bioactives also stimulate bile acid synthesis via CYP7A1 induction, further facilitating cholesterol catabolism and improving overall hepatic lipid flux.

## Clinical Summary

A randomized controlled trial in type 2 diabetic patients with NAFLD (PMID: 32670822) demonstrated that Bergacyn supplementation significantly reduced hepatic steatosis as measured by liver ultrasound and fatty liver index scores. Separate 8–24 week trials in dyslipidemic subjects (PMID: 31225673) reported reductions in LDL-C of approximately 20–30%, total cholesterol decreases of 15–25%, and meaningful triglyceride lowering compared to placebo. Study sample sizes have generally ranged from 50 to 200 participants, and while results are promising, the overall body of evidence remains limited in scale and independent replication is still emerging. Current data supports Bergacyn as a functional adjunct for metabolic liver conditions, though large-scale phase III trials are needed to confirm long-term efficacy and optimal dosing.

## Nutritional Profile

Bergacyn is a standardized combination extract, not a whole food, so traditional macronutrient/micronutrient framing does not apply. Its nutritional identity is defined by its bioactive phytochemical composition: (1) Bergamot (Citrus bergamia) fraction — standardized to contain polyphenolic flavonoids including brutieridin (~3–5% w/w) and melitidin (~2–4% w/w), which are statin-like HMG-CoA reductase inhibitors unique to bergamot; additionally contains naringenin, neoeriocitrin, neohesperidin, and rutin. The bergamot polyphenol fraction (BPF) in commercial extracts is typically standardized to 35–40% total polyphenols. (2) Cynara cardunculus (artichoke/cardoon) fraction — standardized to contain cynarin (1,3-dicaffeoylquinic acid, ~2–5% w/w), chlorogenic acid, luteolin, and apigenin glycosides; also contains silymarin-related flavonoids and sesquiterpene lactones such as cynaropicrin. Cynara extract typically standardized to 2.5–5% caffeoylquinic acids. (3) Combined Bergacyn formulations are commonly dosed at 650–1300 mg/day in clinical trials, with the bergamot:cynara ratio approximately 2:1 by extract weight. Bioavailability: Polyphenols from both sources undergo hepatic first-pass [metabolism](/ingredients/condition/weight-management) and intestinal transformation by gut microbiota into active aglycones; lipophilic flavonoids (brutieridin, melitidin) show enhanced absorption when taken with food. No significant caloric, protein, fat, or fiber contribution at typical supplemental doses.

## Dosage & Preparation

Clinical studies have not specified exact Bergacyn dosages, though related bergamot formulations used 2 pills daily for 8-24 weeks. Preclinical studies used 50 mg/kg/day in mice. No standardization details for flavonoid content are available. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bergacyn is generally well tolerated, with clinical trials reporting no serious adverse events; mild gastrointestinal symptoms such as bloating or loose stools have been noted in a small subset of participants. Because bergamot polyphenols exhibit HMG-CoA reductase inhibitory activity, concurrent use with statin medications may produce additive lipid-lowering effects and warrants physician oversight to avoid excessive LDL reduction or myopathy risk. Cynara cardunculus is contraindicated in individuals with known allergies to plants in the Asteraceae family (e.g., ragweed, chrysanthemum) due to potential cross-reactivity. Safety data in pregnant or breastfeeding women is insufficient, and use during pregnancy should be avoided unless explicitly approved by a healthcare provider.

## Scientific Research

Key clinical evidence includes a randomized, double-blind, placebo-controlled study (PMID: 32670822) showing improved NAFLD biomarkers and reduced [inflammation](/ingredients/condition/inflammation) in T2DM patients. Another RCT (PMC9784233) demonstrated reduced liver steatosis in non-diabetic adults with hepatic steatosis diagnosed by transient elastography. A related bergamot formulation trial (PMID: 31225673) showed lipid improvements in dyslipidemic subjects over 8-24 weeks.

## Historical & Cultural Context

No traditional medicine context was specified for the Bergacyn combination in the research. While bergamot (C. bergamia) has modern clinical applications for cholesterol management, the traditional use of C. cardunculus (wild cardoon) was not detailed in available studies.

## Synergistic Combinations

Milk thistle, berberine, alpha-lipoic acid, artichoke extract, curcumin

## Frequently Asked Questions

### What is Bergacyn and how is it different from plain bergamot extract?

Bergacyn is a patented, fixed-ratio combination of bergamot polyphenol fraction and Cynara cardunculus (artichoke) leaf extract, designed to target both hepatic fat metabolism and systemic lipid regulation simultaneously. Plain bergamot extract lacks the cynarin and luteolin compounds from artichoke that inhibit HMG-CoA reductase and upregulate hepatic LDL receptors, making Bergacyn's dual-action profile distinct from single-ingredient bergamot products.

### How long does it take for Bergacyn to show results for cholesterol?

Clinical trials have reported measurable improvements in LDL-C, total cholesterol, and triglycerides within 8 weeks of daily supplementation, with more pronounced effects observed at the 24-week mark. In dyslipidemic subjects (PMID: 31225673), LDL reductions of 20–30% were documented over this timeframe, suggesting consistent daily use for at least two to three months is necessary to evaluate full therapeutic response.

### Can Bergacyn help with non-alcoholic fatty liver disease (NAFLD)?

Yes, a randomized controlled trial in type 2 diabetic patients with confirmed NAFLD (PMID: 32670822) found that Bergacyn supplementation significantly reduced liver fat accumulation as measured by fatty liver index and ultrasound grading. The mechanism involves AMPK activation in hepatocytes, which suppresses de novo lipogenesis and enhances fatty acid oxidation, directly addressing the metabolic dysfunction driving NAFLD.

### What is the recommended dosage of Bergacyn?

Clinical studies evaluating Bergacyn have typically used doses providing a standardized bergamot polyphenol fraction combined with Cynara cardunculus extract, with total daily doses in published trials generally ranging from 650 mg to 1,000 mg of the combined extract taken once daily with meals. Exact dosing can vary by product formulation, and individuals should follow label guidance or consult a clinician, particularly when combining Bergacyn with lipid-lowering medications.

### Is Bergacyn safe to take with statins?

Bergacyn's bergamot fraction independently inhibits HMG-CoA reductase, the same enzyme targeted by statin drugs, which means combining the two could produce additive or synergistic LDL-lowering effects beyond what either achieves alone. While this combination is not inherently dangerous, it should be supervised by a physician to monitor for excessive lipid reduction and to watch for any potentiation of statin-associated muscle-related side effects, particularly at higher statin doses.

### Does Bergacyn work better for cholesterol management in people with diabetes?

Clinical evidence suggests Bergacyn may be particularly effective for individuals with metabolic dysfunction, including those with diabetes. Studies demonstrating significant improvements in liver fat accumulation and lipid profiles were conducted specifically in diabetic populations, indicating this ingredient may address multiple cardiometabolic concerns simultaneously in this group. However, benefits have also been documented in non-diabetic dyslipidemic subjects, so individual response may vary.

### Can Bergacyn improve blood vessel function and circulation?

Yes, Bergacyn enhances vascular function through improved nitric oxide (NO)-mediated vasodilation, which supports healthy blood vessel flexibility and blood flow. This mechanism complements its cholesterol-lowering effects, as improved vascular function is important for overall cardiovascular health. This dual action on both lipid metabolism and endothelial function distinguishes Bergacyn from single-extract ingredients.

### Is Bergacyn effective for people with elevated triglycerides specifically?

Clinical trials demonstrate that Bergacyn significantly reduces triglyceride levels alongside LDL cholesterol and total cholesterol in dyslipidemic subjects over 8–24 weeks. The combination of bergamot and Cynara cardunculus extracts appears to target triglyceride metabolism more comprehensively than bergamot alone. This makes Bergacyn particularly relevant for individuals whose primary concern is managing elevated triglyceride levels.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*